Carboplatin, Nab-Paclitaxel Demonstrates Efficacy in Small Cell Lung Cancer
the Cancer Therapy Advisor take:
The current standard of therapy for extensive-stage small cell lung cancer (ES-SCLC) is the combination of platinum and etoposide; however, patients on this combination regimen suffer from significant myelosuppresion.
Based on previous trials conducted on single-agent nanoparticle albumin-bound paclitaxel, nab-paclitaxel, for different advanced cancers, investigators hypothesized that the combination therapy of carboplatin and nab-paclitaxel would be better tolerated.
A noncomparative randomized trial was conducted, and the primary objective was to assess the objective response rate. The secondary objectives were progression-free survival, overall survival, and toxicity.
In the study, eligible patients must be diagnosed with ES-SCLC, have an Eastern Cooperative Oncology Group performance status ≤2, and no prior chemotherapy. Patients were then randomly assigned into either arm A (carboplatin area under the curve [AUC] of 6 on day 1 and nab-paclitaxel of 300 mg/m2 on day 1 every 3 weeks) or arm B (carboplatin AUC of 6 on day 1 and nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 every 21 days).
Results showed that a significant number of patients in both arms required dose reductions and/or dose delays, and omission of weekly therapy. Due to the slow accrual, no assessment of efficacy could be made, and thus the trial was terminated early.
Overall, investigators found that the combination of carboplatin and nab-paclitaxel demonstrated activity in ES-SCLC, but required frequent dose modifications. Authors conclude that further prospective trials in disease-specific populations need to be conducted in order to determine the factors that contribute to the tolerability of treatments.
Carboplatin and nab-paclitaxel demonstrated activity in small cell lung cancer, but required frequent dose modifications
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma